Danvers, Massachusetts

Abiomed First Quarter Fiscal 2022 Earnings and Conference Call Notification

Retrieved on: 
Thursday, July 15, 2021
Biotechnology, Health, Cardiology, Medical devices, Abiomed, Danvers, Massachusetts, Companies, NASDAQ, Conference call, Electronic Arts, Economy of the United States, Finance

(NASDAQ: ABMD) announced that on Thursday, August 5, 2021, the Company will release financial results for the first quarter of the fiscal year 2022.

Key Points: 
  • (NASDAQ: ABMD) announced that on Thursday, August 5, 2021, the Company will release financial results for the first quarter of the fiscal year 2022.
  • The Company will host a conference call to discuss the results on Thursday, August 5, 2021 at 8:00 a.m.
  • Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Officer, will host the conference call.
  • Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support.

Abiomed to Present at Upcoming Investor Conferences

Retrieved on: 
Wednesday, February 17, 2021
Biotechnology, Health, Cardiology, Medical devices, Exercise physiology, Branches of biology, Anatomy, Circulatory system, Abiomed, Forward-looking statement, Angiology, Danvers, Massachusetts, Heart, Hemodynamics

Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support.

Key Points: 
  • Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support.
  • Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart.
  • All statements, other than statements of historical facts, may be forward-looking statements.
  • Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release.

Abiomed Continues to Strengthen its Intellectual Property, Now Holds More Than 1,000 Patents

Retrieved on: 
Thursday, January 7, 2021
Biotechnology, Medical devices, Other Health, Health, Cardiology, Abiomed, Danvers, Massachusetts

Abiomed (NASDAQ: ABMD) announces it has surpassed more than 1,000 patents worldwide, with more than 850 additional patents pending.

Key Points: 
  • Abiomed (NASDAQ: ABMD) announces it has surpassed more than 1,000 patents worldwide, with more than 850 additional patents pending.
  • Abiomed is recognized as a leader in technology and innovation, with robust clinical data supporting the regulatory approvals and physician adoption of its technologies.
  • Over the past 20 years, Abiomed has grown its product pipeline by investing more than $600 million in research and development.
  • Based in Danvers, Massachusetts, USA, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support and oxygenation.

Abiomed to Present at the 39th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, December 29, 2020
Health, Medical devices, Cardiology, Abiomed, Financial services, Finance, Companies, JPMorgan Chase, Danvers, Massachusetts

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference (virtual) on Tuesday, January 12, 2021 at 5:20pm EST.

Key Points: 
  • Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference (virtual) on Tuesday, January 12, 2021 at 5:20pm EST.
  • A live webcast of the Company's presentation at the conference will be available via the link JPMorgan Abiomed Webcast .
  • The webcast will also be available on the investor section of the company's website at www.abiomed.com .
  • Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support.

Abiomed to Hold Fireside Chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference

Retrieved on: 
Wednesday, November 25, 2020
Biotechnology, Medical devices, Other Health, Health, Cardiology, Abiomed, Forward-looking statement, Heart, Danvers, Massachusetts

(NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Thursday, December 3, 2020 at 8:30am ET.

Key Points: 
  • (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Thursday, December 3, 2020 at 8:30am ET.
  • Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support.
  • Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart.
  • Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release.

Abiomed to Hold Fireside Chat at the Stephens Annual Investment Conference 2020

Retrieved on: 
Wednesday, November 11, 2020
Professional services, Medical devices, Health, Finance, Banking, Cardiology, Abiomed, Medical specialties, Heart, Circulatory system, Forward-looking statement, Danvers, Massachusetts, Branches of biology, Medicine

(NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the Stephens Annual Investment Conference 2020 (virtual) on Wednesday, November 18, 2020 at 9:00am ET.

Key Points: 
  • (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the Stephens Annual Investment Conference 2020 (virtual) on Wednesday, November 18, 2020 at 9:00am ET.
  • Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support.
  • Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart.
  • Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release.

Cell Signaling Technology Named a Top Charitable Company in Massachusetts by the Boston Business Journal

Retrieved on: 
Thursday, September 24, 2020
Branches of biology, Biology, Cell Signaling Technology, Life sciences, Cell biology, Cell signaling, Danvers, Massachusetts, CST

DANVERS, Massachusetts, Sept. 24, 2020 /PRNewswire/ -- Cell Signaling Technology, Inc. (CST), a discovery technology company and leading provider of antibodies, kits, and services, was named by the Boston Business Journal (BBJ) for the 5th year in a row, as a 2020 top corporate charitable contributor in Massachusetts, at the Annual Corporate Citizenship Awards on September 10th in Boston.

Key Points: 
  • DANVERS, Massachusetts, Sept. 24, 2020 /PRNewswire/ -- Cell Signaling Technology, Inc. (CST), a discovery technology company and leading provider of antibodies, kits, and services, was named by the Boston Business Journal (BBJ) for the 5th year in a row, as a 2020 top corporate charitable contributor in Massachusetts, at the Annual Corporate Citizenship Awards on September 10th in Boston.
  • "We are flattered to be recognized by the Boston Business Journal for our contributions within the Commonwealth of Massachusetts."
  • Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing high quality research tools to the biomedical research community.
  • Cell Signaling Technology and CST are trademarks of Cell Signaling Technology, Inc.

Abiomed to Hold Fireside Chat at the 18th Annual Morgan Stanley Global Healthcare Conference

Retrieved on: 
Tuesday, September 8, 2020
Medical devices, Health, Other Health, General Health, Cardiology, Biotechnology, Abiomed, Medical specialties, Forward-looking statement, Heart, Circulatory system, Danvers, Massachusetts, Medicine, Branches of biology

(NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the 18th Annual Morgan Stanley Global Healthcare Conference (virtual) on Tuesday, September 15th, 2020 at 2:45pm ET.

Key Points: 
  • (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the 18th Annual Morgan Stanley Global Healthcare Conference (virtual) on Tuesday, September 15th, 2020 at 2:45pm ET.
  • Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support.
  • Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart.
  • Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release.

Abiomed to Hold Fireside Chat at the William Blair 40th Annual Growth Stock Conference

Retrieved on: 
Wednesday, June 3, 2020
Professional services, Medical devices, Health, Finance, Banking, Cardiology, Abiomed, Forward-looking statement, RTT, Medical specialties, Danvers, Massachusetts, Circulatory system, Heart, Anatomy

(NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the William Blair 40th Annual Growth Stock Conference (virtual) on Wednesday, June 10, 2020 at 1:20pm CT.

Key Points: 
  • (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the William Blair 40th Annual Growth Stock Conference (virtual) on Wednesday, June 10, 2020 at 1:20pm CT.
    Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support.
  • Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart.
  • This release contains forward-looking statements, including, without limitation, statements regarding development of Abiomed's existing and new products, the company's progress toward commercial growth, and future opportunities and expected regulatory approvals.
  • Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release.

Abiomed to Hold Fireside Chat at Jefferies Virtual Healthcare Conference

Retrieved on: 
Wednesday, May 27, 2020
Biotechnology, Medical devices, Other Health, Health, Cardiology, Abiomed, Medical specialties, Forward-looking statement, Circulatory system, Heart, Danvers, Massachusetts, Anatomy

(NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 10:00am.

Key Points: 
  • (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 10:00am.
  • Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support.
  • Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart.
  • Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release.